Semisynthesis of Some 7-Deoxypaclitaxel Analogs from Taxine B (original) (raw)
Related papers
Synthesis and Biological Evaluation ofN-(Arylsulfanyl)carbonyl Analogues of Paclitaxel (Taxol
Chemistry & Biodiversity, 2006
Four new N-(arylsufanyl)carbonyl paclitaxel analogues (2a–d) were prepared from 7-(triethylsilyl)-protected baccatin III (5). Their cytotoxicities against human ovarian (A2780) and prostate cancer (PC3) cell lines, as well as their tubulin-assembly activities, were determined. In these assays, the new compounds showed rather weak activities, one two orders of magnitude below those of paclitaxel (taxol; 1). The known 3′-N-[(thiophen-2-yl)carbonyl] paclitaxel analogue 3 was also prepared. As previously reported, 3 exhibited strongly improved cytotoxicities and tubulin-assembly activities as compared to paclitaxel (1).
Synthesis and Biological Evaluation of 2-Acyl Analogues of Paclitaxel (Taxol)
J. Med. …, 1998
The anticancer drug paclitaxel (Taxol) has been converted to a large number of 2-debenzoyl-2-aroyl derivatives by three different methods. The bioactivities of the resulting analogues were determined in both tubulin polymerization and cytotoxicity assays, and several analogues with enhanced activity as compared with paclitaxel were discovered. Correlation of cytotoxicity in three cell lines with tubulin polymerization activity showed reasonable agreement. Among the cell lines examined, the closest correlation with antitubulin activity was observed with a human ovarian carcinoma cell line.
Synthesis and bioactivity of a side chain bridged paclitaxel: A test of the T-Taxol conformation
Bioorganic & Medicinal Chemistry Letters, 2009
A knowledge of the bioactive tubulin-binding conformation of paclitaxel (Taxol™) is crucial to a full understanding of the bioactivity of this important anticancer drug, and potentially also to the design of simplified analogs. The bioactive conformation has been shown to be best approximated by the T-Taxol conformation. As a further test of this conclusion, the paclitaxel analog 4 was designed as a compound which has all the chemical functionality necessary for activity, but which cannot adopt the T-Taxol conformation. The synthesis and bioassay of 4 confirmed its lack of activity, and thus provided further support for the T-Taxol conformation as the bioactive tubulin-binding conformation.
Bioorganic & Medicinal Chemistry, 2010
Novel paclitaxel-mimicking alkaloids were designed and synthesized based on a bioactive conformation of paclitaxel, i.e., REDOR-Taxol. The alkaloid 2 bearing a 5-7-6 tricyclic scaffold mimics REDOR-Taxol best among the compounds designed and was found to be the most potent compound against several drug-sensitive and drug-resistant human cancer cell lines. MD simulation study on the paclitaxel mimics 1 and 2 as well as REDOR-Taxol bound to the 1JFF tubulin structure was quite informative to evaluate the level of mimicking. The MD simulation study clearly distinguishes the 5-6-6 and 5-7-6 tricyclic scaffolds, and also shows substantial difference in the conformational stability of the tubulin-bound structures between 2 and REDOR-Taxol. The latter may account for the large difference in potency, and provides critical information for possible improvement in the future design of paclitaxel mimics.
Synthesis and Biological Evaluation of 1-Deoxypaclitaxel Analogues
Journal of Organic Chemistry, 1999
The naturally occurring taxoid baccatin VI has been converted to various 1-deoxypaclitaxel derivatives by selective deacylation followed by attachment of the C-13 side chain. The bioactivities of the resulting analogues were determined in both tubulin polymerization and cytotoxicity assays, and several analogues with activity comparable to that of paclitaxel were discovered. It thus appears that the 1-hydroxyl group is not necessary for the activity of paclitaxel.
Organic Letters, 2006
Supporting Data A. Synthesis 2′-Triisopropylsiloxy-7-triethylsiloxy-bridged-11(15→1)-abeo-paclitaxel (8). Pyridine (0.15 mL) was added to a solution of 7 (18 mg) in anhydrous CH 2 Cl 2 (5 mL). The mixture was cooled to-20 °C and thionyl chloride (53 μL) was added. After stirring for 0.5 h, the reaction was quenched with saturated aqueous NaHCO 3 and extracted with EtOAc. The organic phase was dried under vacuum and the residue was separated by PTLC on silica gel, developed with 8% EtOAc in hexane, to give compound 8 (8.5 mg, 49%) as a white solid. 1 H NMR δ 7.99 (2H, d, J
Synthesis of Paclitaxel. 2. Construction of the ABCD Ring and Formal Synthesis
Organic Letters, 2015
A formal synthesis of the antitumor diterpenoid paclitaxel (Taxol) is described. The ABC ring of paclitaxel, synthesized starting from 1,3-cyclohexanedione and tri-Oacetyl-D-glucal by SmI 2-mediated cyclization as the key transformation, was successfully converted to Takahashi's tetracyclic oxetane intermediate. A double Chugaev reaction was employed for introduction of the strained bridgehead olefin, and stereoselective formation of the oxetane ring afforded the known synthetic intermediate, completing the formal synthesis of paclitaxel.
Synthesis and biological evaluation of C-3′NH/C-10 and C-2/C-10 modified paclitaxel analogues
Bioorganic & Medicinal Chemistry, 2003
Concurrent modifications on the C-3 0 NH/C-10, and C-2/C-10 positions on paclitaxel were carried out as a way of investigating possible synergistic effects. The biological activities of these analogues were evaluated in both a microtubule assembly assay and human ovarian cancer (A2780) and prostate cancer (PC3) cytotoxicity assay. In some cases the doubly modified analogues were more active than would have been predicted based on the activity of the singly modified analogues, indicating probable synergistic effects. #